Seroatlas · Human Serome Atlas

TRIM16L

Tripartite motif-containing protein 16-like protein

Also known as: TR16L_HUMAN

Cross-references: UniProt · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q309B1
Gene: TRIM16L
Canonical length: 348 aa

OverviewNCBI Gene

No narrative summary is available for TRIM16L in this catalog release; identity and structured annotations are shown without generated factual claims.

Canonical amino-acid sequenceUniProt

348 residues, UniProt reviewed canonical sequence.

>Q309B1|TRIM16L
     1  MQFGELLAAV RKAQANVMLF LEEKEQAALS QANGIKAHLE YRSAEMEKSK QELETMAAIS
    61  NTVQFLEEYC KFKNTEDITF PSVYIGLKDK LSGIRKVITE STVHLIQLLE NYKKKLQEFS
   121  KEEEYDIRTQ VSAIVQRKYW TSKPEPSTRE QFLQYVHDIT FDPDTAHKYL RLQEENRKVT
   181  NTTPWEHPYP DLPSRFLHWR QVLSQQSLYL HRYYFEVEIF GAGTYVGLTC KGIDQKGEER
   241  SSCISGNNFS WSLQWNGKEF TAWYSDMETP LKAGPFWRLG VYIDFPGGIL SFYGVEYDSM
   301  TLVHKFACKF SEPVYAAFWL SKKENAIRIV DLGEEPEKPA PSLVGTAP

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against TRIM16L can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.35

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.26
gnomAD pLI: 0
gnomAD missense Z: -0.14

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Cellular components

cytoplasm

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Cytoplasm

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads TRIM16L as an antibody target. Whether an autoantibody or antibody against TRIM16L could matter depends on whether native TRIM16L is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

TRIM16L is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label TRIM16L as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...